A study at The University of Texas MD Anderson Cancer Center identified a new therapeutic target in cancer cells and explains how new anti-cancer drugs called imipridones work by inducing cancer cell death in blood cancers, such as acute myeloid leukaemia (AML) and mantle cell lymphoma.

The study revealed a target in mitochondria, called caseinolytic protease P (ClpP), which, upon activation, breaks down proteins within mitochondria, a process known as mitochondrial proteolysis.

A new class of anti-cancer agents, called imipridones, were shown to activate ClpP and cause cancer cell death via mitochondrial proteolysis.

The drugs, ONC201 and Onc212, work regardless of whether the common tumour suppressor p53 is present in any form.

Findings from the study, led by Michael Andreeff, M.D., Ph.D., professor of leukaemia, and Jo Ishizawa, M.D., Ph.D., assistant professor of leukaemia, were reported in the journal Cancer Cell.

"Despite newly developed targeted agents, the majority of haematologic malignancies and solid tumours are still incurable. This includes essentially all patients with p53 mutations," said Andreeff. "Therefore, anti-tumour agents with novel mechanisms of action are urgently needed. Our findings support the clinical development of imipridones and other ClpP activators for human cancers."

Through in vitro and in vivo models, the team demonstrated that knock-out or over-expression of inactivated mutant ClpP induced complete resistance against ONC201 and ONC212, indicating that activation of ClpP is crucial for cell death caused by the drugs.

Through extensive crystallography studies, the team identified the exact binding sites and binding patters of the drugs on ClpP and demonstrated how they increased protease activity.

While ONC201 is in early clinical trials for AML and other cancers and its pre-clinical efficacy has been established in numerous cancer models, the direct target behind its success has remained elusive.

Pre-clinical toxicology studies have been conducted for ONC212, and it is slated for clinical trials in the near future.

"Deletions or mutations of ClpP have never been reported in primary AML, suggesting that ClpP could be an effective target across the spectrum of molecular and cytogenetic subsets of AML," said Ishizawa.

"Our data indicate that patient samples with the lowest levels of ClpP are less sensitive to ClpP hyperactivation. Thus, levels of ClpP could serve as a biomarker to identify AML patients most likely to respond to this therapy."

Andreeff added that further studies of larger numbers of patients will be required to establish thresholds of ClpP expressions most likely to predict response.

Source and image: University Of Texas MD Anderson Cancer Center